Boston Scientific Lays Groundwork to Shift $15bn from Irish Operation in Major Restructuring
Boston Scientific has completed a balance sheet reorganisation that lays the groundwork to shift $15 billion from its Irish subsidiary to parent companies in the Netherlands and the United States, company filings published this week reveal — a development that arrives as the medical device giant faces a global restructuring programme that has already triggered a collective redundancy notification affecting its Irish workforce of more than 7,000 people.
Background
Boston Scientific is one of the largest employers in the Irish medical device sector, with manufacturing facilities in Galway, Cork, and Clonmel that together employ more than 7,000 people directly and support thousands more in the wider supply chain. The company's Irish operations have been a cornerstone of the Galway medical technology cluster — one of the most significant concentrations of medical device manufacturing in Europe — for more than three decades.
The medical device sector is Ireland's second-largest export industry after pharmaceuticals, and companies like Boston Scientific, Medtronic, and Abbott have made Ireland a globally significant hub for the design and manufacture of cardiovascular, endoscopy, and electrophysiology devices. The sector's presence in Ireland has been built on a combination of favourable corporate tax rates, a skilled engineering workforce, and proximity to European markets — advantages that have attracted sustained investment but also created a degree of dependency on the strategic decisions of a small number of large multinationals.
Boston Scientific announced a company-wide restructuring plan in late July 2026, citing competitive pressures in the US electrophysiology market and slower growth for its Watchman heart device. The company anticipates pre-tax charges of between $700 million and $800 million, with the goal of reducing annual pre-tax expenses by approximately $500 million. The Irish Department of Enterprise confirmed in July that it had received a notification of collective redundancies from the company — a mandatory step for companies planning 30 or more job cuts — though the exact number of Irish roles at risk has not been publicly disclosed.
Key Developments
Company filings published this week reveal that Boston Scientific Medical Device Limited, an Irish subsidiary, completed a balance sheet reorganisation in March 2026. The reorganisation transferred $15 billion from the company's reserves into its profit-and-loss reserve, effectively laying the groundwork to shift these funds out of the Irish operation to parent companies in the Netherlands and the United States. The move is a standard corporate treasury operation but is significant in scale, representing one of the largest such transfers from an Irish subsidiary in recent years.
Despite the restructuring, the company's Irish manufacturing arm reported strong financial performance for the most recent reporting period, with an 18% increase in turnover to $2.07 billion and a 22% rise in pre-tax profits to $135.7 million. The financial strength of the Irish operation makes the restructuring-driven job cuts all the more difficult to explain to workers and their representatives, who argue that the Irish facilities are profitable and productive.
The company's Irish operations were also disrupted on Monday, August 25, by a global network communications outage that forced day-shift staff at the Cork plant to be sent home with full pay, while employees at the Galway and Clonmel plants were offered the option to take unpaid or holiday leave. The outage, which affected Boston Scientific operations globally, was resolved within 24 hours.
Why It Matters
The $15 billion balance sheet reorganisation is a reminder of the structural vulnerability of Ireland's relationship with large multinationals. While the Irish state has benefited enormously from the tax revenues and employment generated by companies like Boston Scientific, the strategic decisions that determine the future of those operations are made in boardrooms in Marlborough, Massachusetts — not in Galway or Cork. The reorganisation does not in itself signal an imminent withdrawal from Ireland, but it does reduce the financial buffers within the Irish subsidiary that might otherwise anchor the company's long-term commitment to its Irish facilities.
The Irish government's response to the restructuring has been cautious. The Department of Enterprise has confirmed it is monitoring the situation and is in contact with the company, but has stopped short of any public intervention. The IDA Ireland, which has a long-standing relationship with Boston Scientific as one of its flagship clients, is understood to be engaged in discussions with the company about the future of its Irish operations, though the outcome of those discussions has not been disclosed.
Local Impact
For the 7,000-plus workers at Boston Scientific's Irish facilities — concentrated in Galway's Ballybrit and Mervue business parks, with additional sites in Cork and Clonmel — the combination of a global restructuring, a collective redundancy notification, and a major balance sheet reorganisation creates significant uncertainty. SIPTU and other unions representing Boston Scientific workers have called for urgent engagement with management to clarify the scale and timeline of any job losses. The Galway Chamber of Commerce has warned that significant job losses at Boston Scientific would have a ripple effect across the city's economy, given the company's role as an anchor employer in the region.
What's Next
Boston Scientific is expected to provide further details of its Irish restructuring plans in the coming weeks, following the conclusion of a mandatory information and consultation process with employee representatives. The company's next quarterly earnings call, scheduled for late October, is expected to include an update on the global restructuring programme. The IDA Ireland has indicated it will publish its annual employment survey for the medical device sector in November, which will provide the first comprehensive picture of the impact of the restructuring on Irish employment figures.
